Access the full text.
Sign up today, get DeepDyve free for 14 days.
D. Jensen, K. Sherman, C. Hézode, S. Pol, S. Zeuzem, V. Lédinghen, A. Tran, M. Elkhashab, Z. Younes, M. Kugelmas, S. Mauss, G. Everson, V. Luketic, J. Vierling, L. Serfaty, M. Brunetto, J. Heo, D. Bernstein, F. Mcphee, D. Hennicken, P. Mendez, E. Hughes, S. Noviello (2015)
Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders.Journal of hepatology, 63 1
N. Antaki, A. Craxì, S. Kamal, R. Moucari, S. Merwe, S. Haffar, A. Gadano, N. Zein, Ching‐lung Lai, J. Pawlotsky, E. Heathcote, G. Dusheiko, P. Marcellin (2010)
The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus reportLiver International, 30
E. Gower, C. Estes, S. Blach, K. Razavi-Shearer, H. Razavi (2014)
Global epidemiology and genotype distribution of the hepatitis C virus infection.Journal of hepatology, 61 1 Suppl
J. Pawlotsky (2013)
NS5A inhibitors in the treatment of hepatitis C.Journal of hepatology, 59 2
A. Abergel, S. Métivier, D. Samuel, D. Jiang, K. Kersey, P. Pang, E. Svarovskaia, S. Knox, V. Loustaud-Ratti, T. Asselah (2016)
Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infectionHepatology, 64
S. Jensen, S. Serre, Daryl Humes, S. Ramirez, Yi-Ping Li, J. Bukh, J. Gottwein (2015)
Substitutions at NS3 Residue 155, 156, or 168 of Hepatitis C Virus Genotypes 2 to 6 Induce Complex Patterns of Protease Inhibitor ResistanceAntimicrobial Agents and Chemotherapy, 59
S. Laperche, K. Sauné, P. Dény, G. Duverlie, S. Alain, M. Chaix, C. Gaudy, F. Lunel, J. Pawlotsky, C. Payan, B. Pozzetto, C. Tamalet, V. Thibault, S. Vallet, F. Bouchardeau, J. Izopet, J. Lefrère (2006)
Unique NS5b Hepatitis C Virus Gene Sequence Consensus Database Is Essential for Standardization of Genotype Determinations in Multicenter Epidemiological StudiesJournal of Clinical Microbiology, 44
B. Besse, M. Coste‐Burel, N. Bourgeois, C. Féray, B. Imbert‐Marcille, E. Andre-Garnier (2012)
Genotyping and resistance profile of hepatitis C (HCV) genotypes 1-6 by sequencing the NS3 protease region using a single optimized sensitive method.Journal of virological methods, 185 1
F. Mcphee, A. Sheaffer, J. Friborg, D. Hernandez, P. Falk, G. Zhai, Steven Levine, Susan Chaniewski, Fei Yu, D. Barry, Chaoqun Chen, Min Lee, Kathy Mosure, Li-Qiang Sun, M. Sinz, N. Meanwell, R. Colonno, J. Knipe, P. Scola (2012)
Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032)Antimicrobial Agents and Chemotherapy, 56
Y. Jeong, B. Kim (2003)
Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection
S. Zeuzem, H. Dvory‐Sobol, D. Brainard (2017)
No Effect Of Resistance-Associated Substitutions In Patients With Rare HCV Subtypes Following Treatment With Sofosbuvir-Containing Regimens
M. Gao, R. Nettles, M. Belema, L. Snyder, V. Nguyen, R. Fridell, Michael Serrano-Wu, D. Langley, Jin‐Hua Sun, Donald II, J. Lemm, Chunfu Wang, J. Knipe, C. Chien, R. Colonno, D. Grasela, N. Meanwell, L. Hamann (2010)
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effectNature, 465
J. Urquijo, M. Diago, J. Boadas, R. Planas, R. Solá, J. Olmo, J. Crespo, J. Erdozaín, M. Antón, C. Arocena, D. Suárez, J. Gine, J. Barrera, Javier Gracia-Samaniego, R. Pérez, B. Dalmau, M. Montoro (2013)
Safety and efficacy of treatment with pegylated interferon alpha-2a with ribavirin in chronic hepatitis C genotype 4.Annals of hepatology, 12 1
S. Akhavan, A. Schnuriger, P. Lebray, Y. Benhamou, T. Poynard, V. Thibault (2009)
Natural variability of NS3 protease in patients infected with genotype 4 hepatitis C virus (HCV): implications for antiviral treatment using specifically targeted antiviral therapy for HCV.The Journal of infectious diseases, 200 4
P. Marcellin, H. Cheinquer, M. Curescu, G. Dusheiko, P. Ferenci, A. Horban, D. Jensen, G. Lengyel, A. Mangia, D. Ouzan, M. Puoti, M. Rodríguez-Torres, M. Shiffman, M. Schmitz, F. Tatsch, M. Rizzetto (2012)
High sustained virologic response rates in rapid virologic response patients in the large real‐world PROPHESYS cohort confirm results from randomized clinical trialsHepatology, 56
E. Andre-Garnier, B. Besse, A. Rodallec, O. Ribeyrol, V. Ferré, C. Luco, L. Guen, N. Bourgeois, J. Gournay, E. Billaud, F. Raffi, M. Coste‐Burel, B. Imbert‐Marcille (2017)
An NS5A single optimized method to determine genotype, subtype and resistance profiles of Hepatitis C strainsPLoS ONE, 12
T. Kanda, Shin Yasui, Masato Nakamura, E. Suzuki, M. Arai, Yuki Haga, Reina Sasaki, Shuang Wu, S. Nakamoto, F. Imazeki, O. Yokosuka (2016)
Daclatasvir plus Asunaprevir Treatment for Real-World HCV Genotype 1-Infected Patients in JapanInternational Journal of Medical Sciences, 13
M. Manns, J. McHutchison, S. Gordon, V. Rustgi, M. Shiffman, R. Reindollar, Z. Goodman, K. Koury, M. Ling, J. Albrecht (2001)
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trialThe Lancet, 358
G. Schnell, R. Tripathi, J. Beyer, T. Reisch, Preethi Krishnan, L. Lu, T. Dekhtyar, C. Hall, R. Vilchez, T. Pilot-matias, Christine Collins (2015)
Hepatitis C Virus Genotype 4 Resistance and Subtype Demographic Characterization of Patients Treated with Ombitasvir plus Paritaprevir/RitonavirAntimicrobial Agents and Chemotherapy, 59
B. Fevery, T. Verbinnen, M. Peeters, Katrien Janssen, J. Witek, W. Jessner, S. Meyer, Oliver Lenz (2017)
Virology analyses of HCV genotype 4 isolates from patients treated with simeprevir and peginterferon/ribavirin in the Phase III RESTORE studyJournal of Viral Hepatitis, 24
C. Sarrazin, E. Lathouwers, M. Peeters, B. Daems, A. Buelens, J. Witek, Y. Wyckmans, B. Fevery, T. Verbinnen, A. Ghys, M. Schlag, A. Baldini, S. Meyer, O. Lenz (2015)
Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region.Antiviral research, 116
H. Makhzangy, G. Esmat, M. Said, M. Elraziky, S. Shouman, R. Refai, C. Rekacewicz, R. Gad, N. Vignier, M. Abdel-hamid, K. Zalata, P. Bedossa, S. Pol, A. Fontanet, M. Mohamed (2009)
Response to pegylated interferon alfa‐2a and ribavirin in chronic hepatitis C genotype 4Journal of Medical Virology, 81
Donald Smith, J. Bukh, C. Kuiken, A. Muerhoff, C. Rice, J. Stapleton, P. Simmonds (2013)
Expanded Classification of Hepatitis C Virus Into 7 Genotypes and 67 Subtypes: Updated Criteria and Genotype Assignment Web ResourceHepatology (Baltimore, Md.), 59
D. Roulot, V. Bourcier, V. Grando, P. Dény, Y. Baazia, H. Fontaine, F. Bailly, L. Castéra, V. Ledinghen, P. Marcellin, R. Poupon, M. Bourliere, J. Zarski, F. Roudot-thoraval (2007)
Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infectionJournal of Viral Hepatitis, 14
H. Kumada, Yoshiyuki Suzuki, K. Ikeda, J. Toyota, Y. Karino, K. Chayama, Y. Kawakami, A. Ido, Kazuhide Yamamoto, K. Takaguchi, N. Izumi, K. Koike, T. Takehara, N. Kawada, M. Sata, H. Miyagoshi, T. Eley, F. Mcphee, A. Damokosh, H. Ishikawa, E. Hughes (2014)
Daclatasvir Plus Asunaprevir for Chronic HCV Genotype 1b InfectionHepatology (Baltimore, Md.), 59
N. Zhou, D. Hernandez, Joseph Ueland, Xiaoyan Yang, Fei Yu, K. Sims, P. Yin, F. Mcphee (2015)
NS5A Sequence Heterogeneity and Mechanisms of Daclatasvir Resistance in Hepatitis C Virus Genotype 4 InfectionThe Journal of Infectious Diseases, 213
Christophe Moreno, C. Hézode, P. Marcellin, S. Bourgeois, S. Francque, D. Samuel, F. Zoulim, J. Grangé, U. Shukla, O. Lenz, S. Ouwerkerk-Mahadevan, B. Fevery, M. Peeters, M. Beumont, W. Jessner (2015)
Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4.Journal of hepatology, 62 5
C. Hézode, G. Hirschfield, W. Ghesquiere, W. Sievert, M. Rodríguez-Torres, S. Shafran, P. Thuluvath, H. Tatum, I. Waked, G. Esmat, E. Lawitz, V. Rustgi, S. Pol, N. Weis, P. Pockros, M. Bourliere, L. Serfaty, J. Vierling, M. Fried, O. Weiland, M. Brunetto, G. Everson, S. Zeuzem, P. Kwo, M. Sulkowski, N. Bräu, D. Hernandez, F. Mcphee, M. Wind-Rotolo, Zhaohui Liu, S. Noviello, E. Hughes, P. Yin, S. Schnittman (2014)
Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised studyGut, 64
J. Messina, Isla Humphreys, A. Flaxman, A. Brown, G. Cooke, O. Pybus, E. Barnes (2014)
Global Distribution and Prevalence of Hepatitis C Virus GenotypesHepatology (Baltimore, Md.), 61
T. Hassanein, K. Sims, M. Bennett, N. Gitlin, E. Lawitz, Tuan Nguyen, L. Webster, Z. Younossi, H. Schwartz, P. Thuluvath, Helen Zhou, B. Rege, F. Mcphee, N. Zhou, M. Wind-Rotolo, E. Chung, Amber Griffies, D. Grasela, D. Gardiner (2015)
A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection.Journal of hepatology, 62 5
A. Alberti, L. Lacoin, E. Morais, C. Lefèvre, S. Abogunrin, I. Iheanacho (2016)
Literature review of the distribution of hepatitis C virus genotypes across EuropeJournal of Medical Virology, 88
S. Vallet, Florent Viron, C. Henquell, H. Guillou-Guillemette, G. Lagathu, F. Abravanel, P. Trimoulet, P. Soussan, E. Schvoerer, Arielle Rosenberg, S. Gouriou, P. Colson, J. Izopet, C. Payan (2011)
NS3 Protease Polymorphism and Natural Resistance to Protease Inhibitors in French Patients Infected with HCV Genotypes 1–5Antiviral Therapy, 16
L. Piroth, Hubert Paniez, A. Taburet, C. Vincent, É. Rosenthal, K. Lacombe, E. Billaud, D. Rey, D. Zucman, F. Bailly, J. Bronowicki, Mélanie Simony, A. Diallo, J. Izopet, J. Aboulker, L. Meyer, J. Molina (2015)
High Cure Rate With 24 Weeks of Daclatasvir-Based Quadruple Therapy in Treatment-Experienced, Null-Responder Patients With HIV/Hepatitis C Virus Genotype 1/4 Coinfection: The ANRS HC30 QUADRIH Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 61 5
C. Hézode, L. Alric, A. Brown, T. Hassanein, M. Rizzetto, M. Buti, M. Bourliere, D. Thabut, E. Molina, V. Rustgi, D. Samuel, F. Mcphee, Zhaohui Liu, P. Yin, E. Hughes, M. Treitel (2015)
Randomized Controlled Trial of the NS5A Inhibitor Daclatasvir plus Pegylated Interferon and Ribavirin for HCV Genotype-4 (COMMAND-4)Antiviral Therapy, 21
T. Asselah, C. Hézode, R. Qaqish, M. Elkhashab, T. Hassanein, G. Papatheodoridis, J. Feld, Christophe Moreno, S. Zeuzem, P. Ferenci, Yao Yu, R. Redman, T. Pilot-matias, N. Mobashery (2016)
Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial.The lancet. Gastroenterology & hepatology, 1 1
E. Andre-Garnier, O. Ribeyrol, J. Gournay, B. Besse, M. Coste‐Burel, Isabelle Mabille-Archambeaud, E. Billaud, C. Biron, S. Pineau, François Raff, B. Imbert‐Marcille (2016)
Emergence of HCV Resistance-Associated Variants in Patients Failing Sofosbuvir-Based Regimens: An Observational CohortAntiviral Therapy, 21
Yoshiyuki Suzuki, K. Ikeda, F. Suzuki, J. Toyota, Y. Karino, K. Chayama, Y. Kawakami, H. Ishikawa, Hideaki Watanabe, Wenhua Hu, T. Eley, F. Mcphee, E. Hughes, H. Kumada (2013)
Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options.Journal of hepatology, 58 4
Supplemental Digital Content is available in the text.
European Journal of Gastroenterology & Hepatology – Wolters Kluwer Health
Published: Mar 1, 2018
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.